Illumina, Inc. vs Norfolk Southern Corporation — how do they compare? Illumina, Inc. trades at $265.01 (market cap $39.95B), while Norfolk Southern Corporation trades at $317.24 (market cap $71.20B). The key difference: Norfolk Southern Corporation is the larger of the two by market cap, and Norfolk Southern Corporation pays a 1.7% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Norfolk Southern Corporation for 33 Days on average.
| ILMN | NSC | |
|---|---|---|
Market Cap | $39.95B | $71.20B |
Volume | 3,169,503 | 555,248 |
Sector | Health | Industrials |
52-Week High | $293.69 | $352.98 |
52-Week Low | $91.00 | $278.19 |
Typical Hold Time | 83 Days | 33 Days |
Enterprise Value | $41.31B | $86.75B |
Dividend Yield | — | 1.7% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Norfolk Southern (NSC) trades at $313.20, down 0.98% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $3.52 exceeding the $3.32 forecast. Key developments include the proposed merger with Union Pacific, which is progressing through regulatory review and expected to close by late 2027. Financial metrics show solid profitability with 21.02% net income margin and 16.97% ROE, though cash flow trends indicate negative net cash flow in both 2025 and 2026.
The investment case balances strong operational performance against merger execution risks and technical weakness. With 44% analyst buy ratings and a $361.86 consensus price target suggesting 15% upside, the stock offers value if merger benefits materialize. However, regulatory hurdles, fuel cost pressures, and bearish technical signals warrant caution for near-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →